Covered recipient · General Payments record
AMIR T FATHI
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$249,637.63
- Reported across 151 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $7,815.50 | 5 |
| Food and Beverage | $686.53 | 8 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Astellas Pharma Global Development | $2,652.00 | 1 |
| E.R. Squibb & Sons, L.L.C. | $2,091.00 | 2 |
| Acerta Pharma LLC | $1,712.50 | 2 |
| ABBVIE INC. | $1,524.71 | 2 |
| Daiichi Sankyo Inc. | $446.16 | 5 |
| Astellas Pharma US Inc | $75.66 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (13)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $1,375.00 | 02/20/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1103134219 | CMS |
| ABBVIE INC. | $149.71 | 12/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103714589 | CMS |
| Astellas Pharma Global Development | $2,652.00 | 09/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1132966511 | CMS |
| Astellas Pharma US Inc | $75.66 | 06/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139371969 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,027.50 | 01/03/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105401437 | CMS |
| AstraZeneca Pharmaceuticals LP | $685.00 | 02/10/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1105616097 | CMS |
| Daiichi Sankyo Inc. | $15.12 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089420676 | CMS |
| Daiichi Sankyo Inc. | $54.00 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089420678 | CMS |
| Daiichi Sankyo Inc. | $130.00 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089420674 | CMS |
| Daiichi Sankyo Inc. | $191.92 | 12/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089420672 | CMS |
| Daiichi Sankyo Inc. | $55.12 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089420670 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,076.00 | 04/16/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1101231887 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.00 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101231961 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.